ReviewJournal of oncology2022
The Roles of Tumor-Associated Macrophages in Prostate Cancer.
Review in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 49 citations in OpenAlex.
- High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Article
- Human Group IIA Secreted Phospholipase AInternational journal of molecular sciences · 2026Review
- Tumor-Associated Macrophage Exosomal miR-142-5p Drives Prostate Cancer Neuroendocrine Differentiation via RERG/Ras/ERK Axis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Natural Products in Prostate Cancer: Crosstalk Among the Gut Microbiome, Androgen Receptor Signaling, and Epigenetic Regulation.International journal of molecular sciences · 2026Review
- Macrophage-derived CTSZ promotes prostate cancer progression via αVβ3 integrin-mediated activation of the AKT/FOXO1/JUNB signaling axis.Cancer cell international · 2026Article
- Nanoparticle Strategies for Bone Metastasis Immunotherapy: Targeting, Immune Reprogramming and Combination Therapy.Pharmaceutics · 2026Review
- Comprehensive profiling reveals Sialyl-Tn upregulation and prognostic value in prostate cancer.bioRxiv : the preprint server for biology · 2026Article
- CD18-targeted peptide-drug conjugate remodels the immunosuppressive tumor microenvironment of prostate cancer by selective depletion of M2 macrophages.NPJ precision oncology · 2026Article
- Macrophage-derived extracellular vesicles in the remodeling of the prostate cancer immune microenvironment and therapeutic resistance.Journal of translational medicine · 2026Review
- POLR2H Serves as a Novel Prognostic Biomarker Correlated with Immune Infiltration in Prostate Cancer.Biochemical genetics · 2026Article
- Interleukin-6 secreted by tumor-associated macrophages promotes proliferation and migration through JAK2/STAT3 signaling pathway in human prostate cancer cells.Prostate international · 2026Article
- Regulatory roles of microRNAs in signaling pathways and their biomarker potential in prostate cancer.Cancer cell international · 2026Review
- Obesogens in Prostate Cancer: An Endocrine and Metabolic Threat.Current obesity reports · 2026Review
- Review
- Acupuncture in remodeling the tumor microenvironment: current status and challenges.Frontiers in immunology · 2026Review
- Immunological and inflammatory biomarkers of localized and locally advanced prostate cancer treated with radiotherapy.Frontiers in immunology · 2026Review
- SLAMF8 Promotes M2 Polarization of Macrophages and Enhances Breast Cancer Proliferation.Breast cancer (Dove Medical Press) · 2026Article
- Exploring the mechanisms of mutual influence between lactylation and macrophage polarization in the context of disease.Clinical and translational medicine · 2025Review
- A secreted signature discriminates indolent from aggressive prostate tumors.World journal of urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The morbidity of prostate cancer (PCa) is rising year by year, and it has become the primary cause of tumor-related mortality in males. It is widely accepted that macrophages account for 50% of the tumor mass in solid tumors and have emerged as a crucial participator in multiple stages of PCa, with the huge potential for further treatment. Oftentimes, tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) behave like M2-like phenotypes that modulate malignant hallmarks of tumor lesions, ranging from tumorigenesis to metastasis. Several clinical studies indicated that mean TAM density was higher in human PCa cores versus benign prostatic hyperplasia (BPH), and increased biopsy TAM density potentially predicts worse clinicopathological characteristics as well. Therefore, TAM represents a promising target for therapeutic intervention either alone or in combination with other strategies to halt the "vicious cycle," thus improving oncological outcomes. Herein, we mainly focus on the fundamental aspects of TAMs in prostate adenocarcinoma, while reviewing the mechanisms responsible for macrophage recruitment and polarization, which has clinical translational implications for the exploitation of potentially effective therapies against TAMs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.